News
12-09-2009, 01:40 AM
Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.
More... (http://www.news-medical.net/news/20091209/Multiple-clinical-study-results-of-ABRAXANE-to-be-presented-by-Abraxis-BioScience.aspx)
More... (http://www.news-medical.net/news/20091209/Multiple-clinical-study-results-of-ABRAXANE-to-be-presented-by-Abraxis-BioScience.aspx)